Climb Bio (NASDAQ: CLYM) shares Q3 2025 results in 8-K filing

Rhea-AI Filing Summary

Climb Bio, Inc. furnished a current report to share that it issued a press release on November 6, 2025 announcing its financial results for the quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 to the report and is incorporated by reference. The company notes that this information is being furnished under the securities laws rather than treated as filed for liability purposes.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001768446false00017684462025-11-062025-11-06

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 06, 2025

Climb Bio, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-40708	83-2273741
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
20 William Street Suite 145
Wellesley Hills, Massachusetts				02481
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (866) 857-2596

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		CLYM		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 6, 2025, Climb Bio, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, whether filed before or after the date hereof and regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Press release of Climb Bio, Inc., dated November 6, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Climb Bio, Inc.
Date:	November 6, 2025	By:	/s/ Aoife Brennan
			Aoife Brennan, M.B., Ch.B. President and Chief Executive Officer

FAQ

What did Climb Bio, Inc. (CLYM) report in this 8-K filing?

Climb Bio, Inc. reported that it issued a press release on November 6, 2025 announcing its financial results for the quarter ended September 30, 2025, and furnished that release as Exhibit 99.1.

Which period do Climb Bio, Inc. (CLYM)'s results in this update cover?

The update covers Climb Bio, Inc.'s financial results for the quarter ended September 30, 2025.

How did Climb Bio, Inc. (CLYM) provide its Q3 2025 financial results?

Climb Bio, Inc. provided its Q3 2025 financial results through a press release dated November 6, 2025, which is attached to the report as Exhibit 99.1.

Is the financial information in Climb Bio, Inc. (CLYM)'s press release considered filed with the SEC?

The company states that the information in Item 2.02 and Exhibit 99.1 is being furnished and is not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934.

Where can investors find the detailed financial figures for Climb Bio, Inc. (CLYM)'s quarter ended September 30, 2025?

Detailed financial figures are contained in the press release attached as Exhibit 99.1 to the report.

Who signed this Climb Bio, Inc. (CLYM) 8-K report?

The report was signed on behalf of Climb Bio, Inc. by Aoife Brennan, M.B., Ch.B., President and Chief Executive Officer, on November 6, 2025.